trial

tDCS & Auditory Hallucinations in Schizophrenia

NCTId NCT02227563
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 3 (actual)
Sponsored by Herzog Hospital
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
3 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-03
Primary completion
2016-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Active TDCS

Sponsors

Herzog HospitalLead Sponsor

Investigators

1
Oded Meiron, PhDPrincipal Investigator

Sites

1 total
Jerusalem, Israel

Facts & assertions

4 sourced
Enrollment
3
Phase
NA
Primary Completion Date
2016-08
Status
TERMINATED
relationships
The graph out of here
drug
Active TDCS
drug
lead_sponsor
Herzog Hospital
company
indication
Schizophrenia
indication
Hallucinations
indication
Schizophrenia
indication
investigator
Oded Meiron, PhD
person